The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Science, Tel Aviv University, Israel.
Department of Translational Molecular Medicine, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
Mol Oncol. 2021 May;15(5):1376-1390. doi: 10.1002/1878-0261.12872. Epub 2020 Dec 14.
Previous studies indicated that microglia cells upregulate the expression of aldolase C (ALDOC) in melanoma cells. The present study using brain-metastasizing variants from three human melanomas explores the functional role of ALDOC in the formation and maintenance of melanoma brain metastasis (MBM). ALDOC overexpression impacted differentially the malignant phenotype of these three variants. In the first variant, ALDOC overexpression promoted cell viability, adhesion to and transmigration through a layer of brain endothelial cells, and amplified brain micrometastasis formation. The cross-talk between this MBM variant and microglia cells promoted the proliferation and migration of the latter cells. In sharp contrast, ALDOC overexpression in the second brain-metastasizing melanoma variant reduced or did not affect the same malignancy features. In the third melanoma variant, ALDOC overexpression augmented certain characteristics of malignancy and reduced others. The analysis of biological functions and disease pathways in the ALDOC overexpressing variants clearly indicated that ALDOC induced the expression of tumor progression promoting genes in the first variant and antitumor progression properties in the second variant. Overall, these results accentuate the complex microenvironment interactions between microglia cells and MBM, and the functional impact of intertumor heterogeneity. Since intertumor heterogeneity imposes a challenge in the planning of cancer treatment, we propose to employ the functional response of tumors with an identical histology, to a particular drug or the molecular signature of this response, as a predictive indicator of response/nonresponse to this drug.
先前的研究表明,小胶质细胞会上调黑色素瘤细胞中醛缩酶 C (ALDOC) 的表达。本研究使用三种人类黑色素瘤的脑转移变体,探索了 ALDOC 在黑色素瘤脑转移 (MBM) 形成和维持中的功能作用。ALDOC 的过表达对这三种变体的恶性表型产生了不同的影响。在第一个变体中,ALDOC 的过表达促进了细胞活力、对脑内皮细胞层的黏附和迁移,并放大了脑微转移的形成。该 MBM 变体与小胶质细胞之间的串扰促进了后者细胞的增殖和迁移。与此形成鲜明对比的是,第二个脑转移黑色素瘤变体中 ALDOC 的过表达减少或不影响相同的恶性特征。在第三个黑色素瘤变体中,ALDOC 的过表达增强了某些恶性特征,同时降低了其他特征。对过表达 ALDOC 的变体进行的生物学功能和疾病途径分析清楚地表明,ALDOC 在第一个变体中诱导了肿瘤进展促进基因的表达,而在第二个变体中则诱导了抗肿瘤进展特性。总体而言,这些结果强调了小胶质细胞与 MBM 之间复杂的微环境相互作用,以及肿瘤间异质性的功能影响。由于肿瘤间异质性给癌症治疗计划带来了挑战,我们建议将具有相同组织学的肿瘤对特定药物或该反应的分子特征的功能反应用作对该药物的反应/无反应的预测指标。